RxDoctor Payments Data

Richard Kemmerlin, MD

Family Medicine · Greenville, SCNPI 1346397486

Payments from drug & device makers

$2,762in general payments, 2019–2025

Across 92 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$545
  • Daiichi Sankyo Inc.$346
  • GSK$277
  • AstraZeneca$249
  • AbbVie$206
  • Novo Nordisk$194
  • plus $946 from 19 others

What the payments were for

  • Food & beverage$2,762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,762 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$90,682
Medicare patients
421
Services billed
2,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$23,096
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$21,743
OzempicSemaglutide12$16,477
Tresiba Flextouch U-200Insulin Degludec26$15,288
LinzessLinaclotide11$6,071
Omeprazole167$2,176
Duloxetine Hcl27$2,166
Tamsulosin Hcl95$1,802
Atorvastatin Calcium157$1,656
Gabapentin54$1,405
Pantoprazole Sodium96$1,381
Levothyroxine Sodium146$1,275
Celecoxib25$1,250
Escitalopram Oxalate48$1,173
Metoprolol Succinate66$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$23,09618 claims
Novo NordiskOzempic$194$16,47712 claims
AbbVieLinzess$206$6,07111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →